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Targeted deletions of complement lectin 
pathway genes improve outcome in traumatic 
brain injury, with MASP-2 playing a major role
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Abstract 
The lectin pathway (LP) of complement activation is believed to contribute to brain inflammation. The study aims to 
identify the key components of the LP contributing to TBI outcome as possible novel pharmacological targets. We 
compared the long‑term neurological deficits and neuropathology of wild‑type mice (WT) to that of mice carrying 
gene deletions of key LP components after experimental TBI. WT or MASP‑2  (Masp2−/−), ficolin‑A  (Fcna−/−), CL‑11 
 (Colec11−/−), MASP‑1/3  (Masp1−/−), MBL‑C  (Mbl2−/−), MBL‑A  (Mbl1−/−) or  MBL−/−  (Mbl1−/−/Mbl2−/−) deficient 
male C57BL/6J mice were used. Mice underwent sham surgery or TBI by controlled cortical impact. The sensorimo‑
tor response was evaluated by neuroscore and beam walk tests weekly for 4 weeks. To obtain a comparative analysis 
of the functional outcome each transgenic line was rated according to a health score calculated on sensorimotor 
performance. For selected genotypes, brains were harvested 6 weeks after injury for histopathological analysis. MASP‑
2−/−,  MBL−/− and FCN‑A−/− mice had better outcome scores compared to WT. Of these, MASP‑2−/− mice had the 
best recovery after TBI, showing reduced sensorimotor deficits (by 33% at 3 weeks and by 36% at 4 weeks). They also 
showed higher neuronal density in the lesioned cortex with a 31.5% increase compared to WT. Measurement of LP 
functional activity in plasma from MASP‑2−/− mice revealed the absence of LP functional activity using a C4b deposi‑
tion assay. The LP critically contributes to the post‑traumatic inflammatory pathology following TBI with the highest 
degree of protection achieved through the absence of the LP key enzyme MASP‑2, underlining a therapeutic utility of 
MASP‑2 targeting in TBI.
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Introduction
Traumatic brain injury (TBI) is associated with a primary 
biomechanical injury that can involve contusion and lac-
eration, diffuse axonal injury, brain swelling and intracra-
nial haemorrhage [1–3] followed by a secondary injury, 
which is caused by the activation of several molecular and 
cellular cascades contributing to brain damage and its 
development over time [4–6]. Secondary insult response 
typically includes blood–brain barrier (BBB) breakdown, 
oxidative stress, glutamate excitotoxicity, and neuroin-
flammation [7–9]. Since the secondary damage evolves 
days after the impact, there are windows of opportunity 
for pharmacological therapeutic intervention.
The complement system, an important component 
of the innate and adaptive immune response, is a major 
coordinator of post-traumatic neuroinflammation and 
secondary neuropathology after TBI [10–14]. Even in 
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absence of infection (which can be an additional com-
plication following TBI) the complement system can be 
activated by endogenous danger signals called damage-
associated molecular patterns (DAMPs) [15]. Depending 
on the signals, complement activation may occur through 
three different pathways, the classical, the alternative 
and the lectin pathway (LP), each composed of specific 
initiators and effector enzymes. Carbohydrate structures 
or acetylated proteins exposed on the surface of damaged 
cells, including apoptotic or necrotic cells and stressed 
endothelium [16], are typical DAMPs recognized by the 
LP. Recognition of these signals by initiator molecules 
leads to activation of the associated serine proteases 
MASPs (MBL-associated serine proteases) and subse-
quent activation of the complement cascade.
There is a growing body of evidence showing that LP 
activation critically contributes to disease severity in 
acute brain injury. Genetic deletion of LP subcomponents 
(MBL or MASP-2) [17–19] or their pharmacological tar-
geting [17, 18] are protective in experimental models of 
brain ischemia. In addition to its role as an LP initiator, 
the recognition subcomponent MBL was shown to pos-
sess direct activity, driving platelet-dependent inflam-
mation and vascular damage following ischemic injury 
[16, 20]. Of note, TBI shares blood perfusion deficits and 
metabolic derangements with ischemic injury [21], thus 
suggesting that similar mechanisms might be involved in 
the traumatic pericore tissue [22], an area subjected to 
post-injury hypoxia [23].
In human TBI contusions, the LP recognition mol-
ecules (MBL, ficolin-1, ficolin-2, ficolin-3 and CL-11/
CL-10) and the enzymes MASP-2 and MASP-3 have 
been found deposited inside and outside the cerebral 
vessels. Importantly, MBL, ficolin-2 and ficolin-3 levels 
are elevated in the brains of TBI compared to non-TBI 
patients and perivascular MASP-2 deposition increase 
with injury severity [23]. These results demonstrate the 
involvement of the LP in TBI pathology, although the 
specific recognition molecules or enzymes which most 
prominently contribute to the TBI sequelae remain elu-
sive. The comparative analysis shown here, identifies 
novel targets for therapeutic intervention, aiming to 
reduce post traumatic inflammatory responses, brain 
tissue loss, and to ameliorate loss of cognitive function 
following TBI. In this study, we compared the neurobe-
havioral outcome and health score up to 4  weeks after 
TBI of wild-type (WT) mice and of mice knocked-out 
for MASP-2 (Masp2−/−), ficolin-A (Fcna−/−), CL-11 
(Colec11−/−), MASP-1/3 (Masp1−/−), MBL-C (Mbl2−/−), 
MBL-A (Mbl1−/−) or  MBL−/− (Mbl1−/−/Mbl2−/−). Our 
results demonstrate that MASP-2 deficiency brings the 
highest protective phenotype, countering long-term 
neuroinflammatory injury following TBI, as shown by 
reduced neuronal deficits and neuronal cell loss com-
pared to wild-type mice.  MBL−/− and FCN-A−/− mice 
were also significantly protected and presented good out-
come scores, indicating that these molecules might be 
relevant initiators of the inflammatory response to TBI.
Methods
Mice
Procedures involving animals and their care were con-
ducted in conformity with institutional guidelines in 
compliance with national and international laws and 
policies (prot.9F5F5.81 authorisation n° 753/2017-PR). A 
total of 61 WT and 57 KO mice were studied. We used 
male 9 week old C57BL/6J mice weighing 22–28 g, either 
WT (purchased from Charles Rivers-Italy) or with tar-
geted deletion of MASP-2, ficolin-A, CL-11, MASP-1/3 
(Masp2−/−, Fcna−/−, Colec11−/−, Masp1−/− Biomedical 
Services, University of Leicester) MBL-C and MBL-A, 
(Mbl2−/− and Mbl1−/− obtained at Mario Negri Institute 
by crossing  MBL−/− mice with WT mice and selecting 
appropriate colony founders). The protocols and details 
of this report are in accordance with ARRIVE guidelines 
(http://www.nc3rs .org.uk/page.asp?id=1357, check list 
provided as supplementary file).
Experimental traumatic brain injury
Mice were anesthetized with isoflurane inhalation 
(induction 5%; maintenance 2%) in an  N2O/O2 (70/30%) 
mixture and placed in a stereotactic frame. Mice were 
then subjected to craniotomy followed by induction of 
controlled cortical impact (CCI) brain injury as previ-
ously described [24–27]. Briefly, the injury was induced 
using a 3 mm diameter rigid impactor driven by a pneu-
matic piston rigidly mounted at an angle of 20° from the 
vertical plane and applied vertically to the exposed dura 
mater, between bregma and lambda, over the left parieto-
temporal cortex. We set an impactor velocity of 5  m/s 
and deformation depth 1 mm, resulting in a severe level 
of injury [28, 29]. The craniotomy was then covered with 
a cranioplasty and the scalp sutured. Sham-operated 
mice received identical anesthesia and surgery without 
craniotomy and brain injury.
Behavioural tests
Sensorimotor deficits were assessed by neuroscore and 
beam walk tests as described previously [22, 28, 30] Neu-
roscore Mice were scored from 4 (normal) to 0 (severely 
impaired) for each of the following: (1) forelimb function 
during walking on the grid and flexion response dur-
ing suspension by the tail; (2) hindlimb function during 
walking on the grid and extension during suspension by 
the tail; (3) resistance to lateral right and left push. The 
best score is 12.
Page 3 of 13Mercurio et al. acta neuropathol commun           (2020) 8:174  
Beam walk The test measures the number of foot 
faults of the mouse walking twice on an elevated, narrow 
wooden beam (5 mm wide and 100 cm long). Before each 
test, mice are trained in three habituation trials. Data are 
expressed as the sum of the number of foot faults during 
the two tests. The best score is 0.
Tissue processing
At 6  weeks after surgery, under deep anesthesia (Keta-
mine 20 mg + Medetomidine 0.2 mg), animals were tran-
scardially perfused with 30 mL of phosphate buffer saline 
(PBS) 0.1  mol/L, pH 7.4, followed by 60  mL of chilled 
paraformaldehyde (4%) in PBS. The brains were carefully 
removed from the skull and post-fixed for 6  h at 4  °C, 
then transferred to 30% sucrose in 0.1 mol/L phosphate 
buffer for 24 h until equilibration. The brains were frozen 
by immersion in isopentane at −45  °C for 3 min before 
being sealed into vials and stored at −80  °C until use. 
Coronal brain 20 μm-thick cryosections were cut serially 
(from bregma + 1.2 mm to bregma − 4 mm) at 200 μm 
intervals and stained with Cresyl violet (Sigma-Aldrich) 
using standard histological protocols [26, 31].
Contusion volume
Eight coronal section from bregma + 0.6 to − 4.0  mm 
were acquired with an Olympus BX-61 Virtual Stage 
microscope using a 2 × objective lens, with a pixel size of 
3.49  µm. Contusion volume was analysed as previously 
described [22].
Neuronal count
The neuronal cell count was performed at 6 weeks after 
TBI. Three 20 μm-thick coronal sections at 0.4, 1.6, and 
2.8 mm posterior to bregma and stained with Cresyl vio-
let (Sigma-Aldrich, St. Louis, MO) were selected from 
each mouse brain to quantify neuronal cell loss. The 
entire sections were acquired with an Olympus BX-61 
Virtual Stage microscope using a 20 × objective lens, 
with a pixel size of 0.346 μm. Acquisition was done over 
10 μm thick stacks, with a step size of 2 μm. The differ-
ent focal planes were merged into a single stack by mean 
intensity projection to ensure consistent focus through-
out the sample. Neuronal count was performed by seg-
menting the cells over a cortical region proximal to the 
lesion and in the corresponding contralateral hemisphere 
and excluding the round-shaped signal sized below the 
area threshold of 25 mm2 that is known to be associated 
with glial cells as reported previously [32]. Quantification 
was performed by Fiji software. Data were expressed as 
the total number of neurons quantified in the selected 
cortical region.
Microglia and astrocyte immunohistochemical analysis
Immunohistochemistry was performed on 20  μm-thick 
coronal sections from perfused mouse brains. The sec-
tions were incubated overnight at 4  °C with primary 
monoclonal antibody anti-mouse glial fibrillary acid pro-
tein (GFAP, 0.5  µg/ml, Millipore, Billerica, MA, USA) 
or anti-mouse CD11b (1.25  µg/ml, Bio rad, Hercules, 
CA, USA). Biotinylated secondary antibodies (7.5  µg/
ml, Vector Laboratories) were used. GFAP and CD11b 
immunopositive cells were identified by reaction with 3,3 
diaminobenzidine-tetrahydrochloride (DAB, Vector Lab-
oratories, Burlingame, CA, USA) as previously described 
[33]. Negative control studies, without the primary anti-
body, were performed in parallel. Three 20 μm-thick cor-
onal sections at 0.4, 1.6, and 2.8 mm posterior to bregma 
were selected from each mouse brain for GFAP and 
CD11b quantification. The entire sections were acquired 
with an Olympus BX-61 Virtual Stage microscope using a 
20 × objective lens, with a pixel size of 0.346 μm. Acqui-
sition was done over 10 μm thick stacks, with a step size 
of 2  μm. The different focal planes were merged into a 
single stack by mean intensity projection to ensure con-
sistent focus throughout the sample. The ipsilateral cor-
tex was analyzed over an area included within a 350 µm 
radius from the contusion edge. Images were analyzed 
using Fiji software. GFAP and CD11b immunostained 
area were expressed as positive pixels/total assessed pix-
els and reported as the percentage of total stained area 
[28]. Microglia shape descriptor analysis was performed 
on image processed through the algorithm previously 
described [21]. Once segmented, the cells were measured 
for the following parameters: area, perimeter, circularity, 
Feret’s diameter (max caliper), aspect ratio and solidity. 
Mean single-cell values for each parameter were used for 
statistics.
MBL‑C deposition in the brain
The brain coronal sections were incubated overnight 
at 4  °C with primary monoclonal antibody anti-mouse 
MBL-C (1 µg/ml; Hycult Biotechnology, Uden, The Neth-
erlands) followed by a secondary biotinylated antibody 
against rat IgG. Positive cells were stained with Tyramide 
Cyanine 5 (Cy5, 1:300, Perkin Elmer, Milan, Italy). Cell 
nuclei were stained with 40-6-diamidino-2-phenylindole 
(Hoechst, 1 mg/ml, Invitrogen, Carlsbad, CA). For nega-
tive control staining, the primary antibody was omitted, 
and no staining was observed. Three 20 μm-thick coro-
nal sections at 0.4, 1.6, and 2.8 mm posterior to bregma 
were selected from each mouse brain for MBL-C quan-
tification. Confocal microscopy was done with a Nikon 
A1 confocal scan unit with a 20 × 0.5 numerical aperture 
(NA) objective, managed by NIS elements software. Tis-
sues were imaged at laser excitation of 405 (for nuclei) 
Page 4 of 13Mercurio et al. acta neuropathol commun           (2020) 8:174 
and 647 (for MBL-C) [34]. Image acquisition was done at 
12-bit, keeping the fluorescent signal in a non-saturated 
range (0–1000 greyscale values). The acquisition was 
done over an area sized 2 × 2.5  mm, positioned in the 
ipsilateral hemisphere along the cortical region proxi-
mal to the lesion, with a pixel size of 0.62 μm. Acquisi-
tion was done over 8.3 μm thick stacks, with a step size 
of 2.075 μm. The different focal planes were merged into 
a single stack by maximum intensity projection to ensure 
consistent focus throughout the sample. Immunostain-
ing for MBL-C was quantified by assessing fluorescence 
intensity using Fiji software. To subtract the background 
signal, a minimum threshold was applied based in the 
highest grayscale value of background [28]. MBL-C signal 
was reported as fluorescence integrated density.
Lectin pathway activity assay
Lectin Pathway activation was quantified using the C4 
cleavage assay developed by Petersen et  al. [35]. The 
assay measures the ability of MASP-2 to cleave human 
C4 added in replacement of endogenous C4 which is 
inactivated. This procedure provides a clean measure 
of MASP-2 activity without interference from endog-
enous C4. Nunc MaxiSorb microtiter plates were coated 
with 100  µl of mannan in coating buffer. After over-
night incubation, wells were blocked with 0.1% human 
serum albumin (HSA) in TBS (10 mM Tris–Cl, 140 mM 
NaCl, pH 7.4), then washed with TBS containing 0.05% 
Tween 20 and 5  mM  CaCl2 (wash buffer). Plasma sam-
ples were diluted in 20 mM Tris–Cl, 1 M NaCl, 10 mM 
 CaCl2, 0.05% Triton X-100, 0.1% HSA, pH 7.4, which 
prevents activation of endogenous C4. The diluted sam-
ples were added to the plate and incubated overnight at 
4  °C. The next day, the plates were washed thoroughly 
with wash buffer, then 0.1 µg of purified human C4 [36] 
in 100 µl of 4 mM barbital, 145 mM NaCl, 2 mM  CaCl2, 
1 mM  MgCl2, pH 7.4, was added to each well. After 1.5 h 
at 37 °C, the plates were washed again, and C4b deposi-
tion was detected using alkaline phosphatase-conjugated 
chicken anti-human C4c (Immunsystem, Uppsala, Swe-
den) and the colorimetric substrate pNPP.
Health score
To obtain a comparative analysis of the functional out-
come, each transgenic line was rated according to a 
health score calculated on sensorimotor performance, 
as shown previously [19]. The neuroscore and beam 
walk performance data sets obtained in WT mice (total 
number = 61) were stratified into four groups according 
to quartiles. Each quartile was attributed a score ranging 
from 4 to 1 corresponding to the best to the worst out-
come, respectively. Each mouse (including WT and KO) 
obtains a final score which is the sum of the weighted 
scores of the two parameters, e.g. the neuroscore 
accounted for 50% and beam walk accounted for 50% 
of the final score. The effect size (odds ratio) was calcu-
lated by a Chi square test using the Woolf logit interval 
for computing the 95% confidence interval, stratifying 
mice in terms of good outcome (defined as a score ≥ 3) 
versus bad outcome (score < 3). Odds ratios are reported 
in the forest plot and quantify the strength of the associa-
tion between the genotype and the TBI outcome. Statis-
tical analysis was performed with the standard software 
package GraphPad Prism (GraphPad Software Inc., San 
Diego, CA, USA, version 7.0); p values lower than 0.05 
were considered significant.
Experimental design and additional statistics
Mice were randomly allocated to surgery and assigned 
across cages and days. To minimize variability, all surger-
ies were performed by the same investigator. Subsequent 
behavioural, histological, immunohistological, and bio-
chemical evaluations were performed blind by another 
investigator. Group size is of 14defined by the formula: 
n = 2σ2f (α, β)/Δ2 (SD in groups = σ, type 1 error α = 0.02, 
type II error β = 0.2, percentage difference between 
groups Δ = 20). Standard deviation to be used in the for-
mula for each assessment was calculated based on pre-
vious experiments with same outcome measures (e.g. 
behavioural deficits), resulting in σ = 16.9 and n = 14.4. 
To limit the use of animals, a post hoc power analysis 
test was done at n = 7 on raw data for each experimen-
tal branch. The experiment was interrupted at n = 7 for 
MBL-C−/− and MBL-A−/− mice since it was unable to 
provide significant differences using a reasonable number 
of animals (Δ = 3.89, σ = 22.49, thus expected n = 668.37). 
For MASP-2−/− mice the experiment was interrupted at 
n = 7 since a significant difference was already in place 
due to a strong protective effect (Δ = 17.76 (3  week) 
Δ = 19.4 (4 week)).
Groups were compared by analysis of variance and post 
hoc testing as indicated in each figure legend. A paramet-
ric or nonparametric test was selected after the Kolmog-
orov–Smirnov test for normality to assess whether the 
data for the groups were normally distributed. The con-
stancy of the variances was checked by the Bartlett test.
Results
MASP‑2−/− mice showed the best outcome after TBI 
with reduced sensorimotor deficits
This study was conducted according to the plans depicted 
in Fig.  1a. Wild-type (WT) or KO mice (including: 
MASP-2−/−, FCN-A−/−, CL-11−/−, MBL-C−/−, MASP-
1/3−/− and MBL-A−/−) were subjected to TBI or sham 
injury. Sensorimotor deficits were assessed weekly for 
4  weeks by neuroscore and beam walk tests. The data 
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related to the sensorimotor performance are summa-
rized in Table 1. The health score and odds ratio data for 
 MBL−/− mice were calculated using previously published 
data from our lab [32]. To obtain a comparative evalua-
tion of the transgenic lines, a health score based on the 
outcome of the two sensorimotor tests was calculated. 
Mice were rated from 1 (bad outcome) to 4 (good out-
come, Fig. 2a).
MASP-2−/− was the most protective genotype, show-
ing a positive association with a good outcome (odds 
ratio 56.3 [95% CI 1.9–1655], p = 0.002).  MBL−/− and 
FCN-A−/− mice were also significantly protected, show-
ing a positive association with a good outcome, but to a 
lesser extent than MASP-2−/− (p = 0.0017 and p = 0.0386; 
odds ratio 36 [2.7–476.3] and 9.1 [0.9–92.4], respec-
tively). CL-11−/− and MBL-C−/− genotypes showed a 
weaker, non-significant association with a good out-
come (p = 0.0566 and p = 0.5582 respectively), whereas 
MASP-1/3−/− and MBL-A−/− mice were not protected 
(p = 0.5570 and p = 0.527 respectively, Fig. 2b).
MASP‑2−/− mice had higher neuronal density than WT 
mice after TBI
Based on the outcome data, we focused on the MASP-
2−/− genotype and assessed the lesion size at 6  weeks 
(neuronal density, GFAP and CD11b immunostaining) 
and the degree of local brain inflammation at 30  min 
(presence of MBL-C in the brain and residual LP activity 
in plasma) (Fig. 1b). At 6 weeks post injury, we observed 
an extensive macroscopic area of cortical tissue loss, 
extending rostrocaudally from bregma + 0.4 to − 3.6 mm, 
both in WT and MASP-2−/− injured mice, without dif-
ferences between the two genotypes (17.2 ± 1.6 vs 
18.6 ± 1.0  mm3 ± SEM Fig.  3a–c). We then assessed the 
neuronal density in a cortical region traced at a distance 
of 350  μm from the contusion edge (Fig.  3d, e) and in 
the corresponding contralateral hemisphere. MASP-
2−/− mice had higher neuronal density than WT mice at 
6 weeks after TBI (31.5%, p < 0.05, Fig. 3g), indicating that 
the absence of MASP-2 functional activity was signifi-
cantly protective against neuronal death after TBI.
MASP‑2−/− mice did not show different astrogliosis 
and microglial activation after TBI
At 6  weeks after TBI, we measured astrogliosis and 
microglial activation quantifying the GFAP and CD11b 
immunopositive area at the edge of the contusion area. 
WT and MASP-2−/− injured mice showed compa-
rable astrogliosis (17.8 ± 2.1 vs 16.5 ± 2.3 staining   % 
area ± SEM) and microglial activation (8.5 ± 1.8 vs 
8.7 ± 1.7 staining   % area ± SEM) when assessed as the 
total stained area (Fig.  4a, b). Since microglia morphol-
ogy is indicative of the state of microglial activation, we 
subsequently analysed microglial cell shape descriptors 
Fig. 1 Experimental design. a WT or KOs mice (including: MASP‑2−/−,  MBL−/−, FCN‑A−/−, CL‑11−/−, MBL‑C−/−, MASP‑1/3−/− and MBL‑A−/−) were 
subjected to TBI or sham injury. Sensorimotor deficits were assessed weekly by neuroscore and beam walk test. The sum of 4‑week performances of 
each mouse genotype has been used to calculate the health score. b MBL brain presence and residual LP activity in plasma was assed in MASP‑2−/− 
and WT TBI mice 30′ after surgery. Histopathological analysis was done for MASP‑2−/− and WT mice at 6 weeks after TBI
Page 6 of 13Mercurio et al. acta neuropathol commun           (2020) 8:174 
[21]. Our analysis revealed that the proinflammatory 
morphology of microglia persists for as long as 6 weeks 
after TBI. Increased size (area, perimeter and Feret diam-
eter) and higher ramified morphology (lower circular-
ity) were observed in the ipsilateral region compared to 
the contralateral hemisphere (p < 0.01). However, no dif-
ferences in microglial morphology were observed when 
comparing WT and MASP-2−/− mice (Fig. 4c, d).
MASP‑2−/− mice had impaired Lectin Pathway activation 
and normal MBL‑C deposition
Since MBL-C deposition can be detected in the brain 
after TBI [32], we measured the relative amount of 
MBL-C deposits in WT and MASP-2−/− injured mice 
30 min (′) after injury (Fig. 5a). We observed an increased 
deposition of MBL-C in TBI mice (compared to sham), 
regardless of the genotype (WT vs MASP-2−/− 1.30 
(± 0.08) × 1011 vs 1.10 (± 0.12) × 1011 fluorescence inte-
grated density ± SEM Fig. 5b) indicating that the absence 
of MASP-2 did not affect the deposition of MBL-C. We 
then tested LP functional activity in mouse plasma using 
a functional in vitro assay [37] on mannan-coated plates, 
which measures LP activation through MBL (92.6 ± 15.2 
vs 7.3 ± 1.7 optical density ± SEM) [38]. The absence of 
C4b deposition shows that MBL driven LP activation 
does not occur in MASP-2−/− TBI mice, indicating that 
not even residual activation of the LP is occurring in 
MASP-2−/− mice following TBI (Fig. 5c).
Discussion
This study compares the long-term outcome after experi-
mental TBI in mouse lines with targeted deficiencies of 
the LP-specific components, namely the recognition 
molecules ficolin-A, CL-11, MBL-C and MBL-A (both 
individually and combined) and the serine-proteases 
MASP-2, MASP-1 and MASP-3. To obtain a compara-
tive outcome analysis, we developed a health score based 
on the neuroscore and beam walk test, two behavioural 
analyses evaluating sensorimotor deficits, over 4  weeks 
of observation. We found that MASP-2−/−,  MBL−/− and 
FCN-A−/− mice had lower neurological deficits after TBI, 
indicating that these LP components are actively involved 
in driving the traumatic lesion and identifies them as pos-
sible pharmacological targets to reduce post-traumatic 
loss of functional activity and to improve recovery and 
clinical outcome.
Table 1 Summary table
Summary of the outcome measures in the MASP-2−/−,  MBL−/−, FCN-A−/−, CL-11−/−, MBL-C−/−, MASP-1/3−/− or MBL-A−/− TBI mice. For  MBL−/−, data were obtained 
from the previous paper by Longhi et al. [32]
Strain 1 week 2 week 3 week 4 week
% of WT p value % of WT p value % of WT p value % of WT p value
MASP‑2−/−
Neuroscore + 11.4 0.6079 + 4.3 0.9605 + 13.6 0.4541 − 5.9 0.8809
Beam Walk + 5.5 0.9608 + 27.9 0.0681 + 32.1 0.0202 + 36 0.0091
MBL−/−
Neuroscore + 33.7 0.0997 + 42.8 0.0023 + 37.2 0.0011 + 35.6 0.0003
Beam Walk + 12.9 0.2972 + 24.03 0.0131 + 25.1 0.0133 + 21.4 0.0742
FCN‑A−/−
Neuroscore + 19.7 0.9253 + 0.37 > 0.9999 − 7.9 0.7784 + 5.3 0.9171
Beam Walk + 6.7 0.9253 + 15 0.5412 + 13 0.685 + 9.9 0.829
CL‑11−/−
Neuroscore + 16 0.4086 + 13.5 0.5552 + 11.2 0.631 + 11.9 0.5552
Beam Walk − 4.9 0.8735 + 11.1 0.3198 + 15.8 0.0711 + 23.5 0.0024
MBL‑C−/−
Neuroscore + 10 > 0.9999 + 2.9 > 0.9999 + 11.1 > 0.9999 − 16.7 0.8796
Beam Walk − 3.5 > 0.9999 − 3.5 > 0.9999 3.6 > 0.9999 + 3.9 > 0.9999
MASP‑1/3−/−
Neuroscore + 9.1 0.9426 + 11.9 0.784 + 8.7 0.8759 − 1.9 0.9976
Beam Walk + 1.07 0.9997 + 0.56 > 0.9999 − 2.6 0.997 0 > 0.9999
MBL‑A−/−
Neuroscore + 4.5 0.9986 + 7.1 0.989 − 2.9 0.9986 − 19.5 0.589
Beam Walk − 10 0.9025 − 4.2 0.9932 − 9.8 0.9133 − 11.01 0.8786
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MASP-2−/− mice had the strongest reduction in 
sensorimotor deficits after TBI, which is in line with 
the key role of this enzyme in driving LP dependent 
complement activation. Of note, 6  weeks after injury, 
MASP-2−/− TBI mice had higher neuronal density in 
the ipsilateral cortex compared to WT TBI mice, an 
important result given the severity of the TBI model 
used which has a major impact on neuronal viabil-
ity and leads to major brain tissue loss. This is similar 
to what is observed in patients suffering from severe 
injury [23].
Our data underline the importance of the LP in 
TBI pathophysiology and identify MASP-2 as a key 
enzyme. Interestingly, neither of the other LP-asso-
ciated enzymes, i.e. MASP-1 or MASP-3 appear to be 
involved in the posttraumatic loss of CNS functions fol-
lowing TBI, since MASP-1/3−/− mice suffered from a 
similar degree of sensorimotor deficits than their WT 
controls. While it is accepted that only MASP-2 can 
generate the C3 convertase of the LP (C4bC2a) through 
its ability to cleave both C4 and C2 [39, 40], MASP-1 
can support MASP-2 functional activity by cleaving C2 
and enhance the conversion of zymogen MASP-2 into 
its enzymatically active form [41, 42].
It has been postulated that MASP-1 is an essential 
activator of MASP-2 [43] based on in vitro experiments 
using MASP-1/3 or MASP-1 deficient sera or sera treated 
with MASP-1 specific inhibitors. However, in in  vivo 
models of MASP-2 dependent pathophysiology, such as 
ischemia reperfusion injury and TBI (reported here), the 
requirement for MASP-1 to activate MASP-2 appears to 
be negligible, since the absence of MASP-1 (or MASP-3) 
does not protect from MASP-2 dependent tissue injury. 
MASP-1 facilitates the conversion of zymogen MASP-2 
into its enzymatically active form, most likely because 
Fig. 2 Association of LP protein deficiency with the behavioral outcome of traumatized mice over 4 weeks. a The health score was obtained 
by rating mice from 4 (good outcome) to 1 (bad outcome) based on quartiles of the neuroscore and beam walk values over the 4 weeks of 
observation. The final score was the sum of the weighted scores of the two parameters, e.g. the neuroscore and beam walk each accounted for 
50% of the final score. b Association (odds ratio; 95% confidence interval) between the genotype and health score. The odds ratio was calculated 
by a Chi square test using the Woolf logit interval for calculating the 95% confidence interval (CI 95%), stratifying mice in terms of good outcome 
(defined as a score ≥ 3) versus bad outcome (score < 3). MASP‑2−/−,  MBL−/− and FCN‑A−/− mice were significantly associated with good outcome 
scores
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the relatively low abundance of MASP-2 compared 
to MASP-1 limits LP-specific trans-activation events 
[44, 45]. In an experimental model of ischemic stroke, 
we reported that combined deficiency of MASP-1 and 
MASP-3 did not affect the ischemic outcome, while that 
of MASP-2 was protective [18]. Therefore, we hypoth-
esized that ischemic brain injury involved a MASP-2 
dependent pathophysiological process, thus underlining 
that MASP-1 is not an essential activator of MASP-2. 
Consistent with this conclusion is our present observa-
tion that the total absence of LP-mediated complement 
activation in MASP-2−/− mice is protecting from post-
traumatic injury, while MASP-1/3 double deficient mice 
show no degree of protection. In this context, it is impor-
tant to keep in mind that MASP-2 can also cleave C3 
directly through a C4 and C2 independent bypass activa-
tion of native C3 [46].
Our study shows that  MBL−/− and FCN-A−/− mice 
were significantly associated with a good outcome score 
indicating that they may be the relevant initiator mol-
ecules. In line with this, we have previously shown the 
effectiveness of targeting MBL in TBI mice by inhibiting 
MBL with Polyman9, a polymannosylated compound, 
which binds to the carbohydrate recognition domain of 
MBL, attenuating sensorimotor deficits up to 4  weeks 
after TBI [28, 32]. As for ficolin-A, the mouse orthologue 
of human ficolin‐2, no data are available on its role in the 
context of brain injury. In TBI patients ficolin-2 has been 
found in the peri-contusional brain area at significantly 
higher levels than in the brain from control patients [23]. 
Its role in TBI has to be further investigated.
A common feature of the initiators of the lectin 
complement pathway is their ability to interact with 
MASP-2 to trigger the activation of the LP. Thus, 
Fig. 3 Histological analysis of lesion at 6 weeks after TBI in WT and MASP‑2−/− mice. a Representative image of Cresyl violet staining in ipsilateral 
and contralateral hemisphere. The lesion volume was evaluated based on the different extents of the ipsilateral and contralateral hemispheres, 
outlined in blue. Scale bar 1 mm. b Representative images of quantified sections for lesion volume at 6 weeks after TBI in WT and MASP‑2−/− mice. 
Distance from bregma in mm is indicated. c Quantification of the lesion showed no differences between WT and MASP‑2−/− mice 6 weeks after 
TBI. The data is shown as a scatter dot plot, line at mean ± SEM (n = 6); Mann–Whitney test. d Anatomical location of area of interest (red box). e 
Positioning of the cortical region of interest (blue outline) for calculating neuronal cell viability, traced at a distance of 350 μm from the contusion 
edge. Scale bar 350 μm. f 20 × high magnified fields of view showing a higher presence of neurons in MASP‑2−/− than WT mice. Scale bars 20 μm. 
g Quantification of neuronal density in the region of interest. MASP‑2−/− mice had higher neuronal density in the ipsilateral cortex than WT mice. 
The data is shown as a scatter dot plot, line at mean ± SEM (n = 5–6); Two‑way Anova followed by Sidak’s post hoc test, *p < 0.05 compared with ipsi 
WT
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MASP-2 should be a more effective target than one of 
the five LP initiators. The data obtained in this work 
supports this notion, as MASP-2 deficiency provides 
better protection against TBI damage than that of a 
specific initiator. However, as previously reported in 
models of ischemia/reperfusion injury, recognition 
molecules can have detrimental effects independently 
from the LP cascade activation [16, 47]. In particular, 
MBL itself has been shown to promote vascular injury 
on endothelial cells having undergone hypoxic stimu-
lus by direct action—including structural damage to 
the endothelial cell cytoskeleton—without requiring 
LP activation [16]. Consistent with this finding, genetic 
deletion of MBL or its pharmacological inhibition were 
sufficient to obtain significant protection in experimen-
tal models of ischemic stroke, where vascular dysfunc-
tion is critical [17, 20, 48]. The fact that in experimental 
TBI, MBL depletion provided a lower degree of protec-
tion than MASP-2 depletion may suggest that the com-
plement-independent vascular effects of MBL are less 
important for TBI pathophysiology. In line with this 
suggestion, the presence of MBL within the TBI-injured 
area was not different in WT and MASP-2−/− mice, 
supporting the hypothesis that LP-independent detri-
mental effects of MBL have a limited contribution to 
TBI sequelae. Moreover, most of the MBL in the lesion 
core area was extravascular, implying that MBL-driven 
vascular effects may be marginal, at variance with what 
happens in ischemic injury.
Microglia activation may contribute to specific behav-
ioural deficits, like sickness behaviour in mice, corre-
sponding to depressive behaviours seen in TBI patients, 
months after injury [49, 50]. Here we report that 
6  weeks after TBI, microglia are still activated, show-
ing increased size and ramifications in ipsi- compared 
to contra-lateral side, with no difference between WT 
and MASP-2−/− mice. We previously found that early 
(48  h) after ischemia/reperfusion injury MASP-2 dele-
tion was associated with microglia presenting typical 
anti-inflammatory morphological features, as opposed to 
the hypertrophic microglial morphology associated with 
the phagocytic activity and pro-inflammatory state pre-
sent in ischemic WT brains [18]. We cannot exclude that 
MASP-2 deletion affected microglia activation at earlier 
time points after TBI, with consequences on the overall 
outcome. However, data show that this effect is no more 
detectable at chronic time points.
It is known that the complement system drives micro-
glia-driven synaptic control in memory loss [51] and in 
chronic neurodegenerative disease like Alzheimer’s [52], 
a possible long-term consequence of TBI [53]. However 
complement-mediated synapse elimination appears to be 
associated with proteins of the classical pathway, particu-
larly C1q, released locally in the brain [52, 54], with no 
specific involvement of the LP, as shown here.
The results presented here, obtained in experimental 
TBI, pointing to MASP-2 as a key enzyme in TBI pathol-
ogy, are in line with what is observed in TBI patients. 
Namely, we previously reported that: (1) the comple-
ment system is fully activated down to the level of the 
formation of the terminal complement complex; (2) the 
lectin pathway components are persistently present, up 
to 5  days post-TBI; and (3) MASP-2 in the brain is sig-
nificantly increased and associated with TBI severity, 
indicated by abnormal pupil reactivity and traumatic sub-
arachnoid haemorrhage [23]. Moreover others reported 
that increased circulating levels of MASP-2 are associ-
ated with a poor outcome at 90 days after injury [55].
It should not be excluded that other pathways of 
complement system may have a role in propagating 
chronic post-TBI pathology. Indeed, we also reported 
an increased presence of MASP-3 in the brains of TBI 
patients compared to control patients [23], supporting a 
role of the alternative pathway in TBI. Indeed pharma-
cological inhibition of the alternative pathway provided 
significant improvements in histological, and functional 
recovery in an experimental model of TBI [56].
Conclusion
This study highlights the significant contribution of LP 
to the post-traumatic inflammatory pathology follow-
ing TBI and shows that the highest degree of protection 
is achieved through the absence of the LP key enzyme 
MASP-2, underlying the therapeutic utility of MASP-2 
targeting following acute brain injury. This points to LP 
(See figure on next page.)
Fig. 4 Inflammation markers and microglia shape descriptors 6 weeks after TBI in WT and MASP‑2−/− mice. a, b MASP‑2 deletion did not affect the 
level of inflammatory markers such as glial fibrillary acidic protein (GFAP) and CD11b. The data is shown as a scatter dot plot, line at mean ± SEM 
(n = 5–6); unpaired t test. c Shape descriptors of CD11b positive cells showed that at 6 weeks after TBI microglia are still activated, having increased 
area, perimeter, Feret diameter and ramifications (indicated by lower circularity) higher in ipsi than in contralateral side. The drawings beside the 
y‑axis indicate the expected values for each parameter depending on cell shape or symmetry. Microglia morphology did not differ between 
the two genotypes. The data is shown as a scatter dot plot, line at mean ± SEM (n = 6); Two‑way Anova followed by Sidak’s post hoc test. d 
Representative high‑magnification images of CD11b positive cells showing activated microglia in the ipsilateral side of both WT and MASP‑2−/− TBI 
mice, scale bar 20 µm
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and MASP-2 as novel pharmacological targets for TBI, 
thus paving the way for future development of clini-
cal strategies. MASP-2 represents a unique target: it is 
a single, low-abundance enzyme that is exclusively syn-
thesized in the liver [57], so the effectiveness of systemic 
MASP-2 inhibitory agents is not complicated by local 
biosynthesis in the brain and the limitations imposed by 
the blood–brain barrier. Of note, an inhibitory antibody 
against MASP-2 (Narsoplimab) is currently undergoing 
phase 3 clinical trials for the treatment of Hematopoi-
etic Stem Cell Transplant-Associated TMA (Clinical-
Trials.gov Identifier: NCT04247906), IgA Nephropathy 
(NCT03608033) and Atypical Hemolytic Uremic Syn-
drome (NCT03205995) and in a phase 2 clinical trial for 
the treatment of Lupus Nephritis (NCT02682407), thus 
making the present work potentially transferable to the 
clinical setting in the near future.
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